Global Medicinal Chemistry for Drug Discovery Market - Industry Trends and Forecast to 2031

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 27
1.1 OBJECTIVES OF THE STUDY 27
1.2 MARKET DEFINITION 27
1.3 OVERVIEW OF GLOBAL MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET 27
1.4 CURRENCY AND PRICING 29
1.5 LIMITATIONS 29
1.6 MARKETS COVERED 30
2 MARKET SEGMENTATION 33
2.1 MARKETS COVERED 33
2.2 GEOGRAPHICAL SCOPE 34
2.3 YEARS CONSIDERED FOR THE STUDY 35
2.4 DBMR TRIPOD DATA VALIDATION MODEL 36
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 39
2.6 MULTIVARIATE MODELLING 40
2.7 MARKET END USER COVERAGE GRID 41
2.8 PROCESS LIFELINE CURVE 42
2.9 DBMR MARKET POSITION GRID 43
2.10 VENDOR SHARE ANALYSIS 45
2.11 SECONDARY SOURCES 46
2.12 ASSUMPTIONS 46
3 EXECUTIVE SUMMARY 47
4 PREMIUM INSIGHTS 51
4.1 PESTEL ANALYSIS 53
4.2 POTERS FIVE FORCES 54
5 GLOBAL MEDICINAL CHEMISTRY IN DRUG DISCOVERY MARKET: REGULATIONS 55
6 MARKET OVERVIEW 59
6.1 DRIVERS 61
6.1.1 INCREASE IN R&D FOR DISCOVERY AND DEVELOPMENT OF NOVEL DRUG MOLECULES 61
6.1.2 RISE IN CHRONIC DISEASES 61
6.1.3 INITIATIVES FOR RESEARCH ON RARE DISEASES AND ORPHAN DRUGS 62
6.1.4 GROWTH IN BIOLOGICS 63
6.1.5 COLLABORATIONS AMONG RESEARCHERS AND PHARMACEUTICAL INDUSTRIES 63

6.2 RESTRAINTS 64
6.2.1 RISE IN COST OF FORMULATED DRUG 64
6.2.2 TECHNICAL RISKS IN MEDICINAL CHEMISTRY FOR DRUG DISCOVERY 64
6.2.3 BIOETHICAL ISSUES IN MEDICINAL CHEMISTRY FOR DRUG DISCOVERY 64
6.3 OPPORTUNITIES 65
6.3.1 ADVANCEMENTS IN BIOCHEMICAL, TRANSLATIONAL, AND MOLECULAR STUDIES 65
6.3.2 RISE IN HEALTHCARE EXPENDITURE 65
6.3.3 USE OF ARTIFICIAL INTELLIGENCE IN MEDICINAL CHEMISTRY FOR DRUG DISCOVERY 66
6.4 CHALLENGES 66
6.4.1 BIOLOGICS NEED SPECIALIST TESTING SERVICES 66
6.4.2 STRINGENT REGULATIONS 67
7 IMPACT OF COVID-19 ON GLOBAL MEDICINAL CHEMISTRY IN DRUG DISCOVERY MARKET 68
7.1 IMPACT ON PRICE 68
7.2 IMPACT ON DEMAND 68
7.3 IMPACT ON SUPPLY CHAIN 69
7.4 STRATEGIC DECISIONS BY MANUFACTURERS 69
7.5 CONCLUSION 70
8 GLOBAL MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY PROCESS 71
8.1 OVERVIEW 72
8.2 TARGET SELECTION 75
8.3 TARGET VALIDATION 75
8.4 HIT-TO-LEAD IDENTIFICATION 76
8.5 LEAD OPTIMIZATION 77
8.6 CANDIDATE VALIDATION 78
9 GLOBAL MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DESIGN 79
9.1 OVERVIEW 80
9.2 FRAGMENT-BASED VARIATION 83
9.3 STRUCTURE BASED DRUG DESIGN 83
9.4 DIVERSITY ORIENTED SYNTHESIS 84
9.5 CHEMOGENOMICS 85
9.6 NATURAL PRODUCTS 86
9.7 OTHERS 87
10 GLOBAL MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DRUG TYPE 88
10.1 OVERVIEW 89
10.2 SMALL MOLECULES 92
10.3 BIOLOGICS 93
11 GLOBAL MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA 94
11.1 OVERVIEW 95
11.2 ONCOLOGY 98
11.3 NEUROLOGY 98
11.4 INFECTIOUS AND IMMUNE SYSTEM DISEASES 99
11.5 CARDIOVASCULAR DISEASES 100
11.6 DIGESTIVE SYSTEM DISEASES 101
11.7 OTHERS 102
12 GLOBAL MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY END USER 103
12.1 OVERVIEW 104
12.2 CONTRACT RESEARCH ORGANIZATION 108
12.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 108
12.4 ACADEMIC AND RESEARCH INSTITUTES 109
12.5 OTHERS 110
13 GLOBAL MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY REGION 111
13.1 OVERVIEW 112
13.2 NORTH AMERICA 117
13.2.1 U.S. 123
13.2.2 CANADA 125
13.2.3 MEXICO 127
13.3 EUROPE 129
13.3.1 GERMANY 135
13.3.2 FRANCE 137
13.3.3 U.K. 139
13.3.4 ITALY 141
13.3.5 SPAIN 143
13.3.6 NETHERLANDS 145
13.3.7 RUSSIA 147
13.3.8 SWITZERLAND 149
13.3.9 BELGIUM 151
13.3.10 TURKEY 153
13.3.11 AUSTRIA 155
13.3.12 NORWAY 157
13.3.13 HUNGARY 159
13.3.14 LITHUANIA 161
13.3.15 IRELAND 163
13.3.16 POLAND 165
13.3.17 REST OF EUROPE 167
13.4 ASIA-PACIFIC 168
13.4.1 CHINA 175
13.4.2 JAPAN 177
13.4.3 INDIA 179
13.4.4 SOUTH KOREA 181
13.4.5 AUSTRALIA 183
13.4.6 SINGAPORE 185
13.4.7 THAILAND 187
13.4.8 PHILIPPINES 189
13.4.9 MALAYSIA 191
13.4.10 INDONESIA 193
13.4.11 VIETNAM 195
13.4.12 REST OF ASIA-PACIFIC 197
13.5 SOUTH AMERICA 198
13.5.1 BRAZIL 204
13.5.2 ARGENTINA 206
13.5.3 PERU 208
13.5.4 REST OF SOUTH AMERICA 210
13.6 MIDDLE EAST AND AFRICA 211
13.6.1 SOUTH AFRICA 217
13.6.2 SAUDI ARABIA 219
13.6.3 U.A.E. 221
13.6.4 EGYPT 223
13.6.5 ISRAEL 225
13.6.6 KUWAIT 227
13.6.7 REST OF MIDDLE EAST AND AFRICA 229
14 GLOBAL MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: COMPANY LANDSCAPE 230
14.1 COMPANY SHARE ANALYSIS: GLOBAL 230
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 231
14.3 COMPANY SHARE ANALYSIS: EUROPE 232
14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 233
15 SWOT ANALYSIS 234

16 COMPANY PROFILE 235
16.1 EUROFINS SCIENTIFIC 235
16.1.1 COMPANY SNAPSHOT 235
16.1.2 REVENUE ANALYSIS 236
16.1.3 COMPANY SHARE ANALYSIS 236
16.1.4 SERVICE PORTFOLIO 236
16.1.5 RECENT DEVELOPMENT 237
16.2 LABCORP DRUG DEVELOPMENT 238
16.2.1 COMPANY SNAPSHOT 238
16.2.2 REVENUE ANALYSIS 239
16.2.3 COMPANY SHARE ANALYSIS 239
16.2.4 SERVICE PORTFOLIO 240
16.2.5 RECENT DEVELOPMENT 240
16.3 CHARLES RIVER 241
16.3.1 COMPANY SNAPSHOT 241
16.3.2 REVENUE ANALYSIS 241
16.3.3 COMPANY SHARE ANALYSIS 242
16.3.4 SERVICE PORTFOLIO 242
16.3.5 RECENT DEVELOPMENTS 242
16.4 WUXI APPTEC 243
16.4.1 COMPANY SNAPSHOT 243
16.4.2 REVENUE ANALYSIS 243
16.4.3 COMPANY SHARE ANALYSIS 244
16.4.4 SERVICE PORTFOLIO 244
16.4.5 RECENT DEVELOPMENTS 244
16.5 EVOTEC SE 245
16.5.1 COMPANY SNAPSHOT 245
16.5.2 REVENUE ANALYSIS 245
16.5.3 COMPANY SHARE ANALYSIS 246
16.5.4 SERVICE PORTFOLIO 246
16.5.5 RECENT DEVELOPMENTS 246
16.6 PIRAMAL PHARMA SOLUTIONS 247
16.6.1 COMPANY SNAPSHOT 247
16.6.2 SERVICE PORTFOLIO 247
16.6.3 RECENT DEVELOPMENTS 247
16.7 THERMO FISHER SCIENTIFIC INC. 248
16.7.1 COMPANY SNAPSHOT 248
16.7.2 REVENUE ANALYSIS 248
16.7.3 SERVICE PORTFOLIO 249
16.7.4 RECENT DEVELOPMENT 249
16.7.4.1 ACQUISITION 249
16.8 AURIGENE PHARMACEUTICAL SERVICES (A SUBSIDIARY OF DR. REDDY'S LABORATORIES) 250
16.8.1 COMPANY SNAPSHOT 250
16.8.2 REVENUE ANALYSIS 250
16.8.3 SERVICE PORTFOLIO 251
16.8.4 RECENT DEVELOPMENT 251
16.9 AURELIA BIOSCIENCES 252
16.9.1 COMPANY SNAPSHOT 252
16.9.2 SERVICE PORTFOLIO 252
16.9.3 RECENT DEVELOPMENTS 252
16.10 BIOBLOCKS INC 253
16.10.1 COMPANY SNAPSHOT 253
16.10.2 SERVICE PORTFOLIO 253
16.10.3 RECENT DEVELOPMENT 253
16.11 CERTARA INC 254
16.11.1 COMPANY SNAPSHOT 254
16.11.2 REVENUE ANALYSIS 254
16.11.3 SERVICE PORTFOLIO 255
16.11.4 RECENT DEVELOPMENTS 255
16.12 DOMAINEX 256
16.12.1 COMPANY SNAPSHOT 256
16.12.2 SERVICE PORTFOLIO 256
16.12.3 RECENT DEVELOPMENT 256
16.13 DRUG DISCOVERY ALLIANCES 257
16.13.1 COMPANY SNAPSHOT 257
16.13.2 SERVICE PORTFOLIO 257
16.13.3 RECENT DEVELOPMENT 257
16.14 GENSCRIPT BIOTECH 258
16.14.1 COMPANY SNAPSHOT 258
16.14.2 REVENUE ANALYSIS 258
16.14.3 SERVICE PORTFOLIO 259
16.14.4 RECENT DEVELOPMENT 259
16.15 JUBILANT BIOSYS 260
16.15.1 COMPANY SNAPSHOT 260
16.15.2 SERVICE PORTFOLIO 260
16.15.3 RECENT DEVELOPMENTS 260
16.16 NANOSYN 262
16.16.1 COMPANY SNAPSHOT 262
16.16.2 PRODUCT PORTFOLIO 262
16.16.3 RECENT DEVELOPMENT 262
16.17 NEREID THERAPEUTICS 263
16.17.1 COMPANY SNAPSHOT 263
16.17.2 SERVICE PORTFOLIO 263
16.17.3 RECENT DEVELOPMENT 263
16.18 PFIZER INC. 264
16.18.1 COMPANY SNAPSHOT 264
16.18.2 REVENUE ANALYSIS 264
16.18.3 SERVICE PORTFOLIO 265
16.18.4 RECENT DEVELOPMENTS 265
16.19 SELVITA 266
16.19.1 COMPANY SNAPSHOT 266
16.19.2 REVENUE ANALYSIS 266
16.19.3 SERVICE PORTFOLIO 267
16.19.4 RECENT DEVELOPMENTS 267
16.19.4.1 ACQUISITION 267
16.20 SPECTRIS PLC 268
16.20.1 COMPANY SNAPSHOT 268
16.20.2 REVENUE ANALYSIS 268
16.20.3 SERVICE PORTFOLIO 269
16.20.4 RECENT DEVELOPMENT 269
16.21 SYGNATURE DISCOVERY 270
16.21.1 COMPANY SNAPSHOT 270
16.21.2 SERVICE PORTFOLIO 270
16.21.3 RECENT DEVELOPMENTS 270
16.22 TAROS CHEMICAL GMBH 271
16.22.1 COMPANY SNAPSHOT 271
16.22.2 SERVICE PORTFOLIO 271
16.22.3 RECENT DEVELOPMENT 271
17 QUESTIONNAIRE 272
18 RELATED REPORTS 275